Return to Sport Protocol

Overview

Returning to sport after injury is one of the most common reasons athletes and active individuals explore peptide protocols. The challenge is balancing the desire for rapid return with the biological reality of tissue healing timelines — tendons, ligaments, and cartilage heal on their own schedule regardless of how urgently an athlete wants to compete again.

This protocol integrates BPC-157 and TB-500 into a structured, phased return-to-sport framework. These two peptides are among the most widely referenced in the injury recovery space due to their complementary mechanisms: BPC-157 promotes angiogenesis and has been studied for tendon, ligament, and gastrointestinal healing, while TB-500 (a fragment of thymosin beta-4) promotes cellular migration, reduces inflammation, and supports tissue remodeling.

This protocol is not a substitute for proper medical evaluation, imaging, and professional rehabilitation. Peptides do not replace physical therapy — they are integrated alongside it.

For immediate post-surgical recovery, see the Post-Surgery Protocol. For chronic tendon issues specifically, see the Tendon Repair Protocol.

Compounds Involved

Compound	Class	Primary Effects	Route	Typical Dose
BPC-157	Gastric pentadecapeptide	Angiogenesis, tendon/ligament repair, anti-inflammatory	SubQ (local or systemic)	250–500 mcg 1–2x/day
TB-500	Thymosin beta-4 fragment	Cell migration, tissue remodeling, anti-inflammatory	SubQ	2–5 mg 2x/week (loading), 2 mg 1x/week (maintenance)
Collagen peptides	Structural protein	Connective tissue substrate	Oral	15–20 g/day
Vitamin C	Cofactor	Collagen synthesis support	Oral	500–1,000 mg/day

BPC-157

Body Protection Compound-157 is a synthetic pentadecapeptide derived from human gastric juice. Preclinical research has demonstrated effects on angiogenesis (new blood vessel formation), fibroblast proliferation, and tendon-to-bone healing. It has been studied in animal models of Achilles tendon transection, ligament damage, muscle crush injury, and bone fracture.

A distinguishing feature of BPC-157 is its versatility of administration. Subcutaneous injection near the injury site (local administration) is the most common approach for musculoskeletal injuries, though systemic injection and oral administration are also used. See BPC-157 for the full compound profile.

TB-500

TB-500 is a synthetic version of the active region of thymosin beta-4, a 43-amino-acid protein involved in cell migration, blood vessel formation, and tissue repair. Its primary mechanism involves upregulation of actin, which promotes cellular motility and allows repair cells to migrate to injury sites more effectively.

TB-500 is typically administered systemically rather than locally, and its effects are generally considered more systemic and anti-inflammatory compared to BPC-157's more targeted tissue repair properties. See TB-500 for the full compound profile.

The Phased Approach

Returning to sport requires respecting tissue healing biology while progressively challenging repaired structures. This protocol divides recovery into four phases aligned with standard rehabilitation principles.

Phase 1: Acute Healing (Weeks 1–3)

Goals: Reduce inflammation, protect injured tissue, begin peptide support

Peptide protocol:

Compound	Dose	Frequency	Route
BPC-157	250–500 mcg	2x daily	SubQ near injury site
TB-500	4–5 mg	2x per week	SubQ (systemic)

Rehabilitation: PEACE (Protection, Elevation, Avoid anti-inflammatories, Compression, Education) protocol. Gentle range-of-motion exercises as pain allows. No loading of the injured structure.

Nutrition: High protein intake (1.6–2.2 g/kg bodyweight), collagen peptides 15–20 g/day with vitamin C 500 mg (taken 30–60 minutes before any rehabilitation exercises), anti-inflammatory foods.

Phase 2: Proliferative Repair (Weeks 4–8)

Goals: Support tissue rebuilding, restore range of motion, begin loading

Peptide protocol:

Compound	Dose	Frequency	Route
BPC-157	250 mcg	2x daily	SubQ near injury site
TB-500	2–3 mg	2x per week	SubQ (systemic)

Rehabilitation: Progressive range-of-motion work, isometric loading of the injured structure, proprioceptive training. Begin pain-free strengthening exercises. Continue working with a physiotherapist.

Key principle: The loading stimulus is essential for proper tissue remodeling. Collagen fibers align along lines of mechanical stress — without appropriate loading, healed tissue will be disorganized and weaker. See the Tendon Repair Protocol for specific loading progressions.

Phase 3: Remodeling and Strengthening (Weeks 9–16)

Goals: Restore full strength and function, sport-specific conditioning

Peptide protocol:

Compound	Dose	Frequency	Route
BPC-157	250 mcg	1x daily	SubQ (can transition to systemic)
TB-500	2 mg	1x per week	SubQ (systemic)

Rehabilitation: Progressive resistance training, eccentric loading (especially for tendon injuries), sport-specific movement patterns at submaximal intensity. Plyometric introduction (for lower-limb injuries). Continue proprioceptive and neuromuscular control work.

Testing milestones:

• Full pain-free range of motion
• Strength within 90% of uninjured side (or pre-injury baseline)
• No pain or swelling during or after exercise

Phase 4: Return to Competition (Weeks 16+)

Goals: Full sport participation, injury risk reduction

Peptide protocol:

Compound	Dose	Frequency	Route
BPC-157	250 mcg	As needed (training days)	SubQ
TB-500	2 mg	Every 2 weeks (maintenance)	SubQ

Rehabilitation: Full training participation with monitoring. Gradual return to competition — practice sessions before competitive matches. Maintain injury prevention exercises long-term. See the Injury Prevention Protocol.

Return-to-play criteria:

• Full strength symmetry (less than 10% deficit)
• Full range of motion
• Completion of sport-specific drills without symptoms
• Psychological readiness and confidence in the injured area

Injection Site Considerations

For musculoskeletal injuries, BPC-157 is commonly administered subcutaneously as close to the injury site as practical:

• Tendon/ligament injuries: Inject into the subcutaneous tissue overlying the affected structure
• Muscle injuries: Inject near the affected muscle belly
• Joint injuries: Inject subcutaneously around the joint capsule (not intra-articular)

TB-500 is typically administered in the abdominal subcutaneous tissue regardless of injury location, as its mechanism relies on systemic distribution and cellular migration.

For proper injection technique, see Subcutaneous Injection and Dosing and Timing.

Timeline Expectations

Tissue healing follows biological timelines that peptides may support but cannot dramatically compress:

Tissue	Typical Healing	Return to Full Load
Muscle strain (Grade 1–2)	2–6 weeks	4–8 weeks
Tendon injury	6–12 weeks	12–24 weeks
Ligament sprain (Grade 2)	6–12 weeks	12–20 weeks
Bone stress injury	6–12 weeks	12–16 weeks
Cartilage	12–24+ weeks	Highly variable

These timelines represent general ranges. Individual healing rates depend on injury severity, blood supply to the area, age, nutrition, and overall health status.

Important Considerations

• Medical evaluation first: Imaging (MRI, ultrasound) and professional assessment should precede any return-to-sport protocol. Peptides do not replace proper diagnosis.
• Anti-doping awareness: Both BPC-157 and TB-500 are prohibited by WADA and most sporting organizations. See the Pre-Competition Protocol and WADA and Peptides for guidance on competitive athlete considerations.
• Do not rush phases: The phased approach exists because premature loading of healing tissue risks re-injury. Each phase has objective criteria that should be met before progression.
• Reconstitution and storage: Both BPC-157 and TB-500 require reconstitution with bacteriostatic water. See Reconstitution and Storage for detailed instructions.
• Quality verification: Source peptides with third-party COAs. See Purity and Testing.

Disclaimer

This article is for educational and informational purposes only. It does not constitute medical advice, and no therapeutic claims are made. Peptide research is ongoing, and individual outcomes may vary. Consult a qualified healthcare professional before beginning any peptide protocol. All compounds discussed are intended for research purposes.